Cargando…

Vaccine allergy: evidence to consider for COVID-19 vaccines

Whereas the COVID-19 pandemic has changed our lives worldwide, we hope that vaccination can combat the disease. We propose how to evaluate suspected severe allergic reactions to the vaccines so that as many as possible may be safely vaccinated. RECENT FINDINGS: Rare cases of severe allergic reaction...

Descripción completa

Detalles Bibliográficos
Autores principales: Nilsson, Lennart, Csuth, Ágnes, Storsaeter, Jann, Garvey, Lene H., Jenmalm, Maria C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270228/
https://www.ncbi.nlm.nih.gov/pubmed/34091550
http://dx.doi.org/10.1097/ACI.0000000000000762
_version_ 1783720758194733056
author Nilsson, Lennart
Csuth, Ágnes
Storsaeter, Jann
Garvey, Lene H.
Jenmalm, Maria C.
author_facet Nilsson, Lennart
Csuth, Ágnes
Storsaeter, Jann
Garvey, Lene H.
Jenmalm, Maria C.
author_sort Nilsson, Lennart
collection PubMed
description Whereas the COVID-19 pandemic has changed our lives worldwide, we hope that vaccination can combat the disease. We propose how to evaluate suspected severe allergic reactions to the vaccines so that as many as possible may be safely vaccinated. RECENT FINDINGS: Rare cases of severe allergic reactions after COVID-19 vaccination have been observed, seemingly at a higher frequency than for other vaccines. Few excipients are likely to have caused these reactions. IgE-mediated reactions to polyethylene glycol (PEG) and its derivatives are the most suspected, albeit hitherto unproven, causes. We suggest to make a diagnosis based on skin tests with PEG and PEG derivatives and that these be considered in relation to the decisions required before the first and the second vaccine dose. A vaccine without these excipients is available, but published data about its side effects are limited. SUMMARY: The underlying immunological mechanisms of the rare severe allergic reactions to the COVID-19 vaccines are poorly understood and need to be clarified. Identifying those who have an undiagnosed allergy to PEG and PEG derivatives is crucial before vaccination, and these substances are found in laxatives, cosmetics and in 30% of all our medications today.
format Online
Article
Text
id pubmed-8270228
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-82702282021-07-12 Vaccine allergy: evidence to consider for COVID-19 vaccines Nilsson, Lennart Csuth, Ágnes Storsaeter, Jann Garvey, Lene H. Jenmalm, Maria C. Curr Opin Allergy Clin Immunol PHARMACOTHERAPY AND EVIDENCE BASED MEDICINE: Edited by Enrico Compalati and Derek Chu Whereas the COVID-19 pandemic has changed our lives worldwide, we hope that vaccination can combat the disease. We propose how to evaluate suspected severe allergic reactions to the vaccines so that as many as possible may be safely vaccinated. RECENT FINDINGS: Rare cases of severe allergic reactions after COVID-19 vaccination have been observed, seemingly at a higher frequency than for other vaccines. Few excipients are likely to have caused these reactions. IgE-mediated reactions to polyethylene glycol (PEG) and its derivatives are the most suspected, albeit hitherto unproven, causes. We suggest to make a diagnosis based on skin tests with PEG and PEG derivatives and that these be considered in relation to the decisions required before the first and the second vaccine dose. A vaccine without these excipients is available, but published data about its side effects are limited. SUMMARY: The underlying immunological mechanisms of the rare severe allergic reactions to the COVID-19 vaccines are poorly understood and need to be clarified. Identifying those who have an undiagnosed allergy to PEG and PEG derivatives is crucial before vaccination, and these substances are found in laxatives, cosmetics and in 30% of all our medications today. Lippincott Williams & Wilkins 2021-08 2021-06-17 /pmc/articles/PMC8270228/ /pubmed/34091550 http://dx.doi.org/10.1097/ACI.0000000000000762 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle PHARMACOTHERAPY AND EVIDENCE BASED MEDICINE: Edited by Enrico Compalati and Derek Chu
Nilsson, Lennart
Csuth, Ágnes
Storsaeter, Jann
Garvey, Lene H.
Jenmalm, Maria C.
Vaccine allergy: evidence to consider for COVID-19 vaccines
title Vaccine allergy: evidence to consider for COVID-19 vaccines
title_full Vaccine allergy: evidence to consider for COVID-19 vaccines
title_fullStr Vaccine allergy: evidence to consider for COVID-19 vaccines
title_full_unstemmed Vaccine allergy: evidence to consider for COVID-19 vaccines
title_short Vaccine allergy: evidence to consider for COVID-19 vaccines
title_sort vaccine allergy: evidence to consider for covid-19 vaccines
topic PHARMACOTHERAPY AND EVIDENCE BASED MEDICINE: Edited by Enrico Compalati and Derek Chu
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270228/
https://www.ncbi.nlm.nih.gov/pubmed/34091550
http://dx.doi.org/10.1097/ACI.0000000000000762
work_keys_str_mv AT nilssonlennart vaccineallergyevidencetoconsiderforcovid19vaccines
AT csuthagnes vaccineallergyevidencetoconsiderforcovid19vaccines
AT storsaeterjann vaccineallergyevidencetoconsiderforcovid19vaccines
AT garveyleneh vaccineallergyevidencetoconsiderforcovid19vaccines
AT jenmalmmariac vaccineallergyevidencetoconsiderforcovid19vaccines